Login to Your Account

Elusys Adds $69M BARDA Contract for Anthrax Antitoxin

By Marie Powers

Friday, September 9, 2011
Elusys Therapeutics Inc. received a contract from the U.S. Biomedical Advanced Research & Development Authority (BARDA) for a second indication for its inhalational anthrax antitoxin Anthim (ETI-204). The five-year contract, totaling up to $68.9 million, is designed to develop an intramuscular (IM) formulation of Anthim for pre- and post-exposure prophylactic use.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription